五味子酯甲和索拉非尼联合用药对晚期肝细胞癌耐药的疗效研究

Study on the Efficacy of Combination Drugs of Schisantherin A and Sorafenib in the Treatment of Drug Resistance in Advanced Hepatocellular Carcinoma

索拉非尼(Sorafenib, So)作为一种治疗晚期肝癌的新型多靶向性一线口服药物,通过抑制酪氨酸酶达到一个良好的治疗效果,能够有效地提高患者的生活质量,延长生存时间。不过从疗效看,索拉非尼因口服生物利用度低、患者存在异质性及耐药性,使其一线治疗的中后期效果不理想。而五味子酯甲(Schisantherin A, SCA)作为抗癌药中的一种,能够通过抑制磷脂酰肌醇3-激酶/蛋白激酶B (PI3K/Akt)信号通路来抑制肺癌细胞的生长和转移,有望改善肝癌细胞对索拉非尼的耐药性,两者联用能否逆转耐药细胞对So的耐药,增强其敏感性,这对填补肝癌二线治疗的大量空白具有重要的临床意义。

Sorafenib (So) is a new multi-targeted first-line oral drug for the treatment of advanced hepatocellular carcinoma, which achieves a good therapeutic effect by inhibiting tyrosinase enzymes and can effectively improve patients’ quality of life and prolong survival time. However, the low oral bioavailability, patient heterogeneity and drug resistance have made sorafenib less effective in the middle and late stages of first-line treatment. Schisantherin A (SCA), one of the anti-cancer drugs, inhibits the growth and metastasis of lung cancer cells by inhibiting the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signalling pathway, which is expected to improve the resistance of liver cancer cells to sorafenib. Whether the combination of the two can reverse the resistance of drug-resistant cells to So and enhance their sensitivity has important clinical implications for filling a large number of gaps in the second-line treatment of hepatocellular carcinoma.